cellgenuity-white_v5_600x159

Developer and manufacturer of biologics, driven to improving patient outcomes by producing the most effective biomaterials for physicians.

CellGenuity develops biologics designed to be used as a therapeutic agent.  Formulated with our patented PūrAMP process, our products are used in a wide range of surgical and non-surgical applications.

PURAMP PROCESS™

Redefining Regenerative Medicine

DONOR SCREENING
PurAMP Processing™
CellGenuity only utilizes gestationally derived biologics from healthy consenting mothers who...
TESTING
PurAMP Processing™
Donor blood samples taken prior to or at the time of recovery were tested by laboratories certified...
PROTECTION
PurAMP Processing™
Donor tissue is recovered using the safest recovery techniques and sterile equipment to protect...

Click on a step in the process to learn more

TRANSPORTATION
PurAMP Processing™
Donated tissue is immediately transported to the lab for processing following our careful collection...
DAY-ONE LAB
PurAMP Processing™
Timing matters. Our production lab begins processing immediately upon receiving the donated...
QUALITY ASSURANCE
PurAMP Processing™
All screening and testing results are reviewed according to the company’s quality management...

AMNIOAMP-MP™

Allograft Patch

AmnioAMP-MP™ is a membrane allograft that may be used as a therapeutic active barrier agent in numerous clinical applications. The membrane forms a protective covering over the wound to preserve tissue structure and biologic integrity.  AmnioAMP-MP™ created with our proprietary PūrAMP Process™, offers mechanical protection and retains nutrient growth factors that are essential for signaling¹².  The product undergoes active preservation of the extracellular matrix (ECM), regulatory proteins, and removal of blood contaminants via a proprietary PūrAMP Process™.  AmnioAMP-MP™ is HCT/P compliant under section 361 of the Public Health Service Act according to 21 CFR Part 1271.10.  This is regulated as human cell product-for homologous use only.

AmnioAllograft™

Purified Amnion Fluid

AmnioAllograft™ is a non structural minimally manipulated liquid allograft derived from amniotic fluid that functions to cushion and protect the fetus in utero.  Amniotic fluid contains vital components, such as nutrients and infection fighting antibodies.  AmnioAllograft™ functions in the same homologous way of providing protection by acting as a shock absorber and temperature control through insulation.  Our PūrAMP Process™ never alters the native, regenerative properties of the allograft tissue; the integrity and characteristics are always maintained. AmnioAllograft™ is HCT/P compliant under section 361 of the Public Health Service Act according to 21 CFR Part 1271.10. This is regulated as human cell product-for homologous use only.

AMNIOAMP-WJ™

Wharton’s Jelly Allograft

AmnioAMP-WJ™ contains isolated Wharton’s Jelly derived from the umbilical cord that provides cushioning and support to the umbilical vein and arteries.  Wharton’s Jelly does not exhibit an immune reaction or rejection, considered “immune privileged”.  Our proprietary PūrAMP Process™ does not alter the original tissue’s function as a Wharton’s Jelly connective tissue, providing physical support and cushioning.  AmnioAMP-WJ™ is regulated as human cell, tissue or cellular-tissue based product (HCT/P) 21 CFR Part 1271.10 and 361 of the Public Health Service Act.  This is regulated as human cell product-for homologous use only.

AMNION

The amniotic membrane (or amnion) is the innermost layer of the placenta that surrounds and provides essential nutrients and immunological protection to the developing fetus. The special composition of cellular components offers mechanical protection and retains nutrient growth factors that are essential for signaling¹². The Amnionic Membrane has been used in medicine for nearly 100 years, while over the last 50 years it has grown to involve multiple fields of medicine and surgery.

amnion_image
  1. Coolen, N.A. et al. (2010).  Comparison between human fetal and adult skin.  Archives of Dermatological Research, 302(3), 4755.
  2. Rowlatt, U. (1979).  Intrauterine wound healing in a 20-week fetus.  Virchows Arch A Pathol Anat Histol, 381(3), 353361.

PHYSICIANS?

Join the other physicians that are finding the value in the “DAY-ONE” Process and products developed by CellGenuity. Click here to get connected with our team.

Home

RECONSTRUCT | REPAIR | REPLACE

Cell Genuity